questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Mécanismes moléculaires de l'action pharmacologique
Antienzymes
Antienzymes : Questions médicales fréquentes
Termes MeSH sélectionnés :
Complement Inactivating Agents
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antienzymes : Questions médicales les plus fréquentes",
"headline": "Antienzymes : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antienzymes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-26",
"dateModified": "2025-04-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antienzymes"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Mécanismes moléculaires de l'action pharmacologique",
"url": "https://questionsmedicales.fr/mesh/D045504",
"about": {
"@type": "MedicalCondition",
"name": "Mécanismes moléculaires de l'action pharmacologique",
"code": {
"@type": "MedicalCode",
"code": "D045504",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des protéines activatrices de la 5-lipoxygénase",
"alternateName": "5-Lipoxygenase-Activating Protein Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D058946",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des protéines activatrices de la 5-lipoxygénase",
"code": {
"@type": "MedicalCode",
"code": "D058946",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.086"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'acétaldéhyde déshydrogénase",
"alternateName": "Acetaldehyde Dehydrogenase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065086",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'acétaldéhyde déshydrogénase",
"code": {
"@type": "MedicalCode",
"code": "D065086",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.089"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'adénosine désaminase",
"alternateName": "Adenosine Deaminase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D058892",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'adénosine désaminase",
"code": {
"@type": "MedicalCode",
"code": "D058892",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.092"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des adénylate cyclases",
"alternateName": "Adenylyl Cyclase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000067956",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des adénylate cyclases",
"code": {
"@type": "MedicalCode",
"code": "D000067956",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.108"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la calcineurine",
"alternateName": "Calcineurin Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065095",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la calcineurine",
"code": {
"@type": "MedicalCode",
"code": "D065095",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.174"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'anhydrase carbonique",
"alternateName": "Carbonic Anhydrase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D002257",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'anhydrase carbonique",
"code": {
"@type": "MedicalCode",
"code": "D002257",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.200"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs et modulateurs de la gamma-secrétase",
"alternateName": "Gamma Secretase Inhibitors and Modulators",
"url": "https://questionsmedicales.fr/mesh/D000091062",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs et modulateurs de la gamma-secrétase",
"code": {
"@type": "MedicalCode",
"code": "D000091062",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.315"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des enzymes du cytochrome P-450",
"alternateName": "Cytochrome P-450 Enzyme Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065607",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des enzymes du cytochrome P-450",
"code": {
"@type": "MedicalCode",
"code": "D065607",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP1A2",
"alternateName": "Cytochrome P-450 CYP1A2 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065609",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP1A2",
"code": {
"@type": "MedicalCode",
"code": "D065609",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.120"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2B6",
"alternateName": "Cytochrome P-450 CYP2B6 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065686",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2B6",
"code": {
"@type": "MedicalCode",
"code": "D065686",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.260"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2C8",
"alternateName": "Cytochrome P-450 CYP2C8 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065687",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2C8",
"code": {
"@type": "MedicalCode",
"code": "D065687",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.308"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2C19",
"alternateName": "Cytochrome P-450 CYP2C19 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065689",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2C19",
"code": {
"@type": "MedicalCode",
"code": "D065689",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.319"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2C9",
"alternateName": "Cytochrome P-450 CYP2C9 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065688",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2C9",
"code": {
"@type": "MedicalCode",
"code": "D065688",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.329"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2D6",
"alternateName": "Cytochrome P-450 CYP2D6 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065690",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2D6",
"code": {
"@type": "MedicalCode",
"code": "D065690",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.368"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2E1",
"alternateName": "Cytochrome P-450 CYP2E1 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065691",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2E1",
"code": {
"@type": "MedicalCode",
"code": "D065691",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.421"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP3A",
"alternateName": "Cytochrome P-450 CYP3A Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065692",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP3A",
"code": {
"@type": "MedicalCode",
"code": "D065692",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.503"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Antifoliques",
"alternateName": "Folic Acid Antagonists",
"url": "https://questionsmedicales.fr/mesh/D005493",
"about": {
"@type": "MedicalCondition",
"name": "Antifoliques",
"code": {
"@type": "MedicalCode",
"code": "D005493",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.350"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de désacétylase d'histone",
"alternateName": "Histone Deacetylase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D056572",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de désacétylase d'histone",
"code": {
"@type": "MedicalCode",
"code": "D056572",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.360"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'intégrase",
"alternateName": "Integrase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D019429",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'intégrase",
"code": {
"@type": "MedicalCode",
"code": "D019429",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.375"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la lipoxygénase",
"alternateName": "Lipoxygenase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D016859",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la lipoxygénase",
"code": {
"@type": "MedicalCode",
"code": "D016859",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.480"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la monoamine oxydase",
"alternateName": "Monoamine Oxidase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D008996",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la monoamine oxydase",
"code": {
"@type": "MedicalCode",
"code": "D008996",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.616"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la synthèse d'acide nucléique",
"alternateName": "Nucleic Acid Synthesis Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D019384",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la synthèse d'acide nucléique",
"code": {
"@type": "MedicalCode",
"code": "D019384",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.675"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'ornithine décarboxylase",
"alternateName": "Ornithine Decarboxylase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065108",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'ornithine décarboxylase",
"code": {
"@type": "MedicalCode",
"code": "D065108",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.705"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phosphodiestérase",
"alternateName": "Phosphodiesterase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D010726",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phosphodiestérase",
"code": {
"@type": "MedicalCode",
"code": "D010726",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.735"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phosphodiestérase-3",
"alternateName": "Phosphodiesterase 3 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D058987",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phosphodiestérase-3",
"code": {
"@type": "MedicalCode",
"code": "D058987",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.735.249"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phosphodiestérase-4",
"alternateName": "Phosphodiesterase 4 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D058988",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phosphodiestérase-4",
"code": {
"@type": "MedicalCode",
"code": "D058988",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.735.374"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phosphodiestérase-5",
"alternateName": "Phosphodiesterase 5 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D058986",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phosphodiestérase-5",
"code": {
"@type": "MedicalCode",
"code": "D058986",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.735.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des phosphoinositide-3 kinases",
"alternateName": "Phosphoinositide-3 Kinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000081082",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des phosphoinositide-3 kinases",
"code": {
"@type": "MedicalCode",
"code": "D000081082",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.736"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phospholipase A2",
"alternateName": "Phospholipase A2 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D064801",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phospholipase A2",
"code": {
"@type": "MedicalCode",
"code": "D064801",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.737"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de prolyle hydroxylases",
"alternateName": "Prolyl-Hydroxylase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D064800",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de prolyle hydroxylases",
"code": {
"@type": "MedicalCode",
"code": "D064800",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.740"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de protéases",
"alternateName": "Protease Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D011480",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de protéases",
"code": {
"@type": "MedicalCode",
"code": "D011480",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'enzyme de conversion de l'angiotensine",
"alternateName": "Angiotensin-Converting Enzyme Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000806",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'enzyme de conversion de l'angiotensine",
"code": {
"@type": "MedicalCode",
"code": "D000806",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.085"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des vasopeptidases",
"alternateName": "Vasopeptidase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000075563",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des vasopeptidases",
"code": {
"@type": "MedicalCode",
"code": "D000075563",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.085.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des vasopeptidases",
"alternateName": "Vasopeptidase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000075563",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des vasopeptidases",
"code": {
"@type": "MedicalCode",
"code": "D000075563",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.085.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la cystéine protéinase",
"alternateName": "Cysteine Proteinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D015853",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la cystéine protéinase",
"code": {
"@type": "MedicalCode",
"code": "D015853",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.325"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des caspases",
"alternateName": "Caspase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D061945",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des caspases",
"code": {
"@type": "MedicalCode",
"code": "D061945",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.325.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des caspases",
"alternateName": "Caspase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D061945",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des caspases",
"code": {
"@type": "MedicalCode",
"code": "D061945",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.325.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de métalloprotéinases matricielles",
"alternateName": "Matrix Metalloproteinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D061965",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de métalloprotéinases matricielles",
"code": {
"@type": "MedicalCode",
"code": "D061965",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.610"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du protéasome",
"alternateName": "Proteasome Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D061988",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du protéasome",
"code": {
"@type": "MedicalCode",
"code": "D061988",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.705"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la rénine",
"alternateName": "Renin Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000092502",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la rénine",
"code": {
"@type": "MedicalCode",
"code": "D000092502",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.753"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la sérine protéinase",
"alternateName": "Serine Proteinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D015842",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la sérine protéinase",
"code": {
"@type": "MedicalCode",
"code": "D015842",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de serine peptidase de type Kazal",
"alternateName": "Serine Peptidase Inhibitors, Kazal Type",
"url": "https://questionsmedicales.fr/mesh/D000074162",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de serine peptidase de type Kazal",
"code": {
"@type": "MedicalCode",
"code": "D000074162",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.562"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Serpines",
"alternateName": "Serpins",
"url": "https://questionsmedicales.fr/mesh/D015843",
"about": {
"@type": "MedicalCondition",
"name": "Serpines",
"code": {
"@type": "MedicalCode",
"code": "D015843",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.675"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs trypsiques",
"alternateName": "Trypsin Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D014361",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs trypsiques",
"code": {
"@type": "MedicalCode",
"code": "D014361",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.900"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de serine peptidase de type Kazal",
"alternateName": "Serine Peptidase Inhibitors, Kazal Type",
"url": "https://questionsmedicales.fr/mesh/D000074162",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de serine peptidase de type Kazal",
"code": {
"@type": "MedicalCode",
"code": "D000074162",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.562"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Serpines",
"alternateName": "Serpins",
"url": "https://questionsmedicales.fr/mesh/D015843",
"about": {
"@type": "MedicalCondition",
"name": "Serpines",
"code": {
"@type": "MedicalCode",
"code": "D015843",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.675"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs trypsiques",
"alternateName": "Trypsin Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D014361",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs trypsiques",
"code": {
"@type": "MedicalCode",
"code": "D014361",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.900"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de protéines kinases",
"alternateName": "Protein Kinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D047428",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de protéines kinases",
"code": {
"@type": "MedicalCode",
"code": "D047428",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.755"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des Janus kinases",
"alternateName": "Janus Kinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000075242",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des Janus kinases",
"code": {
"@type": "MedicalCode",
"code": "D000075242",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.755.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de protéine-tyrosine kinase",
"alternateName": "Tyrosine Protein Kinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000092004",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de protéine-tyrosine kinase",
"code": {
"@type": "MedicalCode",
"code": "D000092004",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.755.875"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la synthèse protéique",
"alternateName": "Protein Synthesis Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D011500",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la synthèse protéique",
"code": {
"@type": "MedicalCode",
"code": "D011500",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.760"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la pompe à protons",
"alternateName": "Proton Pump Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D054328",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la pompe à protons",
"code": {
"@type": "MedicalCode",
"code": "D054328",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.848"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Agents découplants",
"alternateName": "Uncoupling Agents",
"url": "https://questionsmedicales.fr/mesh/D014475",
"about": {
"@type": "MedicalCondition",
"name": "Agents découplants",
"code": {
"@type": "MedicalCode",
"code": "D014475",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.936"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Antienzymes",
"alternateName": "Enzyme Inhibitors",
"code": {
"@type": "MedicalCode",
"code": "D004791",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Xiaoxi Liu",
"url": "https://questionsmedicales.fr/author/Xiaoxi%20Liu",
"affiliation": {
"@type": "Organization",
"name": "Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "Robert S Magin",
"url": "https://questionsmedicales.fr/author/Robert%20S%20Magin",
"affiliation": {
"@type": "Organization",
"name": "Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "Nathan J Schauer",
"url": "https://questionsmedicales.fr/author/Nathan%20J%20Schauer",
"affiliation": {
"@type": "Organization",
"name": "Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "Sara J Buhrlage",
"url": "https://questionsmedicales.fr/author/Sara%20J%20Buhrlage",
"affiliation": {
"@type": "Organization",
"name": "Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu."
}
},
{
"@type": "Person",
"name": "R Gentry Wilkerson",
"url": "https://questionsmedicales.fr/author/R%20Gentry%20Wilkerson",
"affiliation": {
"@type": "Organization",
"name": "Department of Emergency Medicine, University of Maryland School of Medicine, 110 South Paca Street, 6th Floor, Suite 200, Baltimore, MD 21201, USA. Electronic address: gwilkerson@som.umaryland.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s.",
"datePublished": "2023-05-04",
"url": "https://questionsmedicales.fr/article/37149117",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clim.2023.109629"
}
},
{
"@type": "ScholarlyArticle",
"name": "Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition.",
"datePublished": "2023-01-14",
"url": "https://questionsmedicales.fr/article/36732204",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.blre.2023.101041"
}
},
{
"@type": "ScholarlyArticle",
"name": "Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.",
"datePublished": "2023-04-18",
"url": "https://questionsmedicales.fr/article/37072660",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12325-023-02510-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial.",
"datePublished": "2022-08-09",
"url": "https://questionsmedicales.fr/article/35945604",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12931-022-02126-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Antibiofilm agents with therapeutic potential against enteroaggregative Escherichia coli.",
"datePublished": "2022-10-06",
"url": "https://questionsmedicales.fr/article/36201560",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pntd.0010809"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mécanismes moléculaires de l'action pharmacologique",
"item": "https://questionsmedicales.fr/mesh/D045504"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antienzymes",
"item": "https://questionsmedicales.fr/mesh/D004791"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antienzymes - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antienzymes",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antienzymes",
"description": "Comment diagnostiquer une inhibition enzymatique ?\nQuels symptômes indiquent une inhibition enzymatique ?\nQuels tests sont utilisés pour détecter les antienzymes ?\nPeut-on utiliser l'imagerie pour diagnostiquer ?\nQuels marqueurs biochimiques sont associés aux antienzymes ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Complement+Inactivating+Agents&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antienzymes",
"description": "Quels sont les symptômes d'une inhibition enzymatique ?\nL'inhibition enzymatique peut-elle causer des douleurs ?\nY a-t-il des symptômes spécifiques selon l'enzyme inhibée ?\nLes symptômes sont-ils toujours présents ?\nComment les symptômes évoluent-ils avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Complement+Inactivating+Agents&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antienzymes",
"description": "Comment prévenir l'inhibition enzymatique ?\nLes vaccinations peuvent-elles prévenir des inhibitions enzymatiques ?\nY a-t-il des habitudes de vie à adopter ?\nLes contrôles médicaux réguliers sont-ils importants ?\nL'éducation sur les médicaments est-elle nécessaire ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Complement+Inactivating+Agents&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antienzymes",
"description": "Quels traitements existent pour l'inhibition enzymatique ?\nLes antienzymes sont-ils utilisés en chimiothérapie ?\nComment les inhibiteurs enzymatiques sont-ils administrés ?\nY a-t-il des effets secondaires aux antienzymes ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Complement+Inactivating+Agents&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antienzymes",
"description": "Quelles complications peuvent survenir avec l'inhibition enzymatique ?\nL'inhibition enzymatique peut-elle entraîner des maladies chroniques ?\nY a-t-il des risques de surdosage avec les antienzymes ?\nComment gérer les complications liées aux antienzymes ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Complement+Inactivating+Agents&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antienzymes",
"description": "Quels sont les facteurs de risque d'inhibition enzymatique ?\nL'âge influence-t-il le risque d'inhibition enzymatique ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nLe mode de vie affecte-t-il le risque ?\nLes médicaments peuvent-ils être des facteurs de risque ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Complement+Inactivating+Agents&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une inhibition enzymatique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des analyses biochimiques évaluent l'activité enzymatique."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une inhibition enzymatique ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue, la douleur abdominale ou des troubles digestifs peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les antienzymes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'activité enzymatique et les dosages spécifiques d'anticorps sont courants."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour diagnostiquer ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie peut aider à évaluer les organes affectés, mais n'est pas spécifique aux antienzymes."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biochimiques sont associés aux antienzymes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux d'enzymes spécifiques dans le sang peuvent indiquer une inhibition enzymatique."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une inhibition enzymatique ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleurs abdominales, nausées, et troubles métaboliques."
}
},
{
"@type": "Question",
"name": "L'inhibition enzymatique peut-elle causer des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des douleurs dues à des troubles digestifs ou métaboliques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques selon l'enzyme inhibée ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes varient selon l'enzyme affectée, comme la lactase ou la lipase."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains patients peuvent être asymptomatiques malgré une inhibition enzymatique."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver si l'inhibition persiste sans traitement approprié."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'inhibition enzymatique ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et l'évitement de substances toxiques peuvent aider."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles prévenir des inhibitions enzymatiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent prévenir des infections qui causent des inhibitions enzymatiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes de vie à adopter ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter l'alcool et le tabac peut réduire le risque d'inhibition enzymatique."
}
},
{
"@type": "Question",
"name": "Les contrôles médicaux réguliers sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des contrôles réguliers permettent de détecter précocement des problèmes enzymatiques."
}
},
{
"@type": "Question",
"name": "L'éducation sur les médicaments est-elle nécessaire ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, comprendre les effets des médicaments aide à prévenir les inhibitions enzymatiques."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour l'inhibition enzymatique ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments spécifiques et des modifications diététiques."
}
},
{
"@type": "Question",
"name": "Les antienzymes sont-ils utilisés en chimiothérapie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains antienzymes sont utilisés pour cibler des enzymes dans les cellules cancéreuses."
}
},
{
"@type": "Question",
"name": "Comment les inhibiteurs enzymatiques sont-ils administrés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être administrés par voie orale, intraveineuse ou topique selon le cas."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux antienzymes ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme des nausées, des éruptions cutanées ou des douleurs peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le traitement est souvent adapté en fonction de la cause et de la gravité de l'inhibition."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'inhibition enzymatique ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des troubles métaboliques ou des maladies organiques peuvent survenir."
}
},
{
"@type": "Question",
"name": "L'inhibition enzymatique peut-elle entraîner des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une inhibition prolongée peut contribuer à des maladies chroniques comme le diabète."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de surdosage avec les antienzymes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un surdosage peut entraîner des effets indésirables graves et des complications."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées aux antienzymes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi médical régulier et des ajustements de traitement."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié et rapide."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'inhibition enzymatique ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des maladies héréditaires et des habitudes alimentaires."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'inhibition enzymatique ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente souvent avec l'âge en raison de la dégradation enzymatique naturelle."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies auto-immunes peuvent augmenter le risque d'inhibition enzymatique."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils être des facteurs de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent interférer avec l'activité enzymatique et augmenter le risque."
}
}
]
}
]
}
The objective of this study was to characterize the complement-inhibiting activity of SAR445088, a novel monoclonal antibody specific for the active form of C1s. Wieslab® and hemolytic assays were use...
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening, acquired disease in which blood cells lacking complement regulatory proteins are destroyed because of uncontrolled complement act...
Hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) is complement-mediated due to the lack of complement inhibitors in the hemopoietic cell membranes, making complement inhibition the best approach...
The expert recommendations presented here were created using a Delphi-like process by a group of expert PNH specialists across Central Europe. Based on an initial advisory board meeting discussion, re...
Using a systematic approach, literature databases were searched for relevant studies, and 50 articles were reviewed by the experts and included as supporting evidence....
Implementation of these recommendations uniformly across healthcare institutions will promote the best use of complement inhibition in managing PNH, and has the potential to positively impact patient ...
The efficacy and safety of complement inhibition in COVID-19 patients is unclear....
A multicenter randomized controlled, open-label trial. Hospitalized COVID-19 patients with signs of systemic inflammation and hypoxemia (PaO...
81 patients were randomly assigned to zilucoplan (n = 55) or the control group (n = 26). 78 patients were included in the safety and primary analysis. Most were men (87%) and the median age was 63 yea...
Administration of zilucoplan to COVID-19 patients in this proof-of-concept randomized trial was well tolerated under antibiotic prophylaxis. While not reaching statistical significance, indicators of ...
Enteroaggregative Escherichia coli (EAEC) is a predominant but neglected enteric pathogen implicated in infantile diarrhoea and nutrient malabsorption. There are no non-antibiotic approaches to dealin...
We used EAEC strains, 042 and MND005E in a medium-throughput crystal violet-based antibiofilm screen. Hits were confirmed in concentration-dependence, growth kinetic and time course assays and activit...
In all, five compounds (1.25%) reproducibly inhibited biofilm accumulation by at least one strain by 30-85% while inhibiting growth by under 10%. Hits exhibited potent antibiofilm activity at concentr...
This study identified five compounds, not previously described as anti-adhesins or Gram-negative antibacterials, with significant EAEC antibiofilm activity. Molecule, MMV687800 targets the EAEC Aap. I...
In the absence of head-to-head trials, this study compared treatment outcomes with the C3 complement inhibitor pegcetacoplan versus the C5 complement inhibitor eculizumab or ravulizumab in complement ...
A matching-adjusted indirect comparison was conducted using individual patient data from the pegcetacoplan arm of the PRINCE trial (NCT04085601; n = 34) and aggregate data from the ravulizumab (n = 12...
After weighting, treatment with pegcetacoplan was associated with statistically significant improvements in most clinical endpoints compared with ravulizumab or eculizumab treatment. These included: g...
Pegcetacoplan provides clinical benefits as first-line treatment for complement inhibitor-naïve patients with PNH....
ClinicalTrials.gov identifier, NCT04085601....
The Phase 3 single-arm COMMODORE 3 study (ClinicalTrials.gov, NCT04654468) evaluated efficacy and safety of crovalimab (novel C5 inhibitor) in complement inhibitor-naive patients with paroxysmal noctu...
We systematically reviewed the literature on the prevalence of geographic atrophy (GA) in Nordic populations, conducted meta-analyses on age-stratified estimates, and calculated current and future num...
A male in his teens with a history of liver transplant for biliary atresia (aged 2 years) and autoimmune haemolytic anaemia (AIHA, aged 6 years) presented with jaundice, dark urine, fatigue and chest ...
Although complement component 5 inhibitors (C5is) eculizumab and ravulizumab improve paroxysmal nocturnal hemoglobinuria (PNH) outcomes, patients may experience persistent anemia. This post hoc analys...
Patients with PNH and hemoglobin ≥10.0 g/dL at baseline of PADDOCK (N = 6), PRINCE (N = 8), and PEGASUS (N = 11) were included. Before receiving pegcetacoplan, PADDOCK and PRINCE patients were C5i-nai...
From baseline to week 16, mean (SD) hemoglobin concentrations increased in C5i-naive patients (PADDOCK: 10.5 [0.4] to 12.7 [1.1] g/dL; PRINCE: 11.3 [1.0] to 14.0 [1.3] g/dL) and those with suboptimal ...
Patients with PNH and mild/moderate anemia who were C5i-naive or who had suboptimal hemoglobin concentrations despite eculizumab treatment had improved hematologic outcomes and reduced fatigue after i...
Trial registration numbers: PADDOCK (NCT02588833), PRINCE (NCT04085601; EudraCT, 2018-004220-11), PEGASUS (NCT03500549)....